LB4330

DRUG3 trials

Sponsors

L & L Bio Co., Ltd., Ningbo, China

Conditions

Cervical CancerSolid Tumor

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）

TerminatedNCT05707676

L & L Bio Co., Ltd., Ningbo, ChinaSolid Tumor

Start: 2022-11-30End: 2024-12-20Updated: 2025-09-11

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

RecruitingNCT06468358

L & L Bio Co., Ltd., Ningbo, ChinaSolid Tumor

Start: 2024-06-19End: 2027-12-30Target: 194Updated: 2025-09-11

Phase 2

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

Not yet recruitingNCT07177716

L & L Bio Co., Ltd., Ningbo, ChinaCervical Cancer

Start: 2025-10-31End: 2028-12-31Target: 120Updated: 2025-09-17

Related Papers

Phase I/II study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in combination with LB4330, a long-acting IL-10, in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-27

A phase 1 study of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated (TAA) CD8+T cells in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-01

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-011 citations